4-(dimethylamino)-2-methyl-8-quinolinol | 167834-48-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-(dimethylamino)-2-methyl-8-quinolinol
• 英文别名: 8-hydroxy-2-methyl-4-dimethylaminoquinoline；4-(dimethylamino)-2-methylquinolin-8-ol
• CAS: 167834-48-2
• 化学式: C₁₂H₁₄N₂O
• 分子量: 202.256
• InChiKey: RUYLNLZKAUTGGN-UHFFFAOYSA-N

物化性质

• 熔点：
  192-196 °C(Solv: hexane (110-54-3))
• 沸点：
  342.5±37.0 °C(Predicted)
• 密度：
  1.193±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  36.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(dimethylamino)-2-methyl-8-quinolinol 在 1-(3-dimethylaminopropyl)-3-ethoxycarbodiimide hydrochloride 、 4 A molecular sieve 、 四丁基碘化铵 、 potassium carbonate 、 1-羟基苯并三唑 、 一水合肼 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 4-[(1E)-3-({2-[2,4-dichloro-3-({[4-(dimethylamino)-2-methyl-8-quinolinyl]oxy}methyl)methylanilino]-2-oxoethyl}amino)-3-oxo-1-propenyl]-N,N-dimethylbenzamide
  参考文献：
  名称：

  A New Series of Highly Potent Non-Peptide Bradykinin B₂ Receptor Antagonists Incorporating the 4-Heteroarylquinoline Framework. Improvement of Aqueous Solubility and New Insights into Species Difference

  摘要：

  Introduction of nitrogen-containing heteroaromatic groups at the 4-position of the quinoline moiety of our non-peptide B-2 receptor antagonists resulted in enhancing binding affinities for the human B-2 receptor and reducing binding affinities for the guinea pig one, providing new structural insights into species difference. A CoMFA study focused on the diversity of the quinoline moiety afforded correlative and predictive QSAR models of binding for the human B-2 receptor but not for the guinea pig one. A series of 4-(I-imidazolyl)quinoline derivatives could be dissolved in a 5% aqueous solution of citric acid up to a concentration of 10 mg/mL. A representative compound 48a inhibited the specific binding of [H-3]BK to the cloned human B-2 receptor expressed in Chinese hamster ovary cells with an IC50 value of 0.26 nM and significantly inhibited BK-induced bronchoconstriction in guinea pigs even at 1 mug/kg by intravenous administration.

  DOI：

  10.1021/jm030159x
• 作为产物：
  描述：

  4-羟基-8-甲氧基-2-甲基喹啉 在 三溴化硼 、 N,N-二甲基苯胺 、 三氯氧磷 作用下， 反应 20.0h， 生成 4-(dimethylamino)-2-methyl-8-quinolinol
  参考文献：
  名称：

  A New Series of Highly Potent Non-Peptide Bradykinin B₂ Receptor Antagonists Incorporating the 4-Heteroarylquinoline Framework. Improvement of Aqueous Solubility and New Insights into Species Difference

  摘要：

  Introduction of nitrogen-containing heteroaromatic groups at the 4-position of the quinoline moiety of our non-peptide B-2 receptor antagonists resulted in enhancing binding affinities for the human B-2 receptor and reducing binding affinities for the guinea pig one, providing new structural insights into species difference. A CoMFA study focused on the diversity of the quinoline moiety afforded correlative and predictive QSAR models of binding for the human B-2 receptor but not for the guinea pig one. A series of 4-(I-imidazolyl)quinoline derivatives could be dissolved in a 5% aqueous solution of citric acid up to a concentration of 10 mg/mL. A representative compound 48a inhibited the specific binding of [H-3]BK to the cloned human B-2 receptor expressed in Chinese hamster ovary cells with an IC50 value of 0.26 nM and significantly inhibited BK-induced bronchoconstriction in guinea pigs even at 1 mug/kg by intravenous administration.

  DOI：

  10.1021/jm030159x

文献信息

• Heterocyclic compounds as bradykinin antagonists
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US06344462B1

  公开（公告）日：2002-02-05

  This invention relates to a compound of the formula: wherein A1 is lower alkylene, R1 is substituted quinolyl, etc., R2 is hydrogen, halogen or lower alkyl, R3 is halogen or lower alkyl, and R4 is a group of the formula: —Q—A2—R5, etc.,  in which R5 is amino, acylamino, etc., A2 is lower alkylene or a single bond, and Q is a group of the formula:  and pharmaceutically acceptable salts thereof, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to methods of using the same therapeutically in the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.

  这项发明涉及一种化合物，其化学式为：其中A1是较低的烷基烯，R1是取代的喹啉基等，R2是氢、卤素或较低的烷基，R3是卤素或较低的烷基，R4是式的一个基团：—Q—A2—R5等，其中R5是氨基、酰胺基等，A2是较低的烷基烯或一个单键，Q是式的一个基团：，以及其在药学上可接受的盐，制备方法，包含相同化合物的药物组成，以及在治疗人类或动物的布雷金激肽或其类似物介导的疾病的预防和/或治疗中使用的方法。
• [EN] PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS<br/>[FR] PYRIDOPYRIMIDONES, QUINOLEINES ET HETEROCYCLES AZOTES FUSIONNES COMME ANTAGONISTES DE LA BRADYKININE
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：WO1996013485A1

  公开（公告）日：1996-05-09

  (EN) The invention relates to Pyridopyrimidones, Quinolines and fused N-heterocyclic compounds of formula (I) wherein Z is a group of the formula (a) or (b) in which X1 is N or C-R1, X2 is N or C-R9, X3 is N or C-R2, R1 is lower alkyl, R2 is hydrogen, lower alkyl, etc., R9 is hydrogen or lower alkyl, R3 is halogen, etc., R4 is halogen, etc., R5 is a group of formula (c), etc., A is lower alkylene, and Y is O, etc., and pharmaceutically acceptable salts thereof, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to methods of using the same therapeutically in the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.(FR) L'invention concerne des composés de la formule (I) dans laquelle Z est un groupe de la formule (a) ou (b). Dans ces formules, X1 est N ou C-R1, X2 est N ou C-R9, X3 est N ou C-R2, R1 est un alkyle inférieur, R2 est un hydrogène, un alkyle inférieur etc; R9 est un hydrogène ou un alkyle inférieur, R3 est un halogène, etc., R4 est un halogène, etc; R5 est un groupe de la formule (c) etc., dans laquelle A est un alkylène inférieur et Y est O, etc. L'invention concerne également les sels de ces composés acceptables sur le plan pharmaceutique, des procédés pour leur préparation, des compositions pharmaceutiques les contenant, ainsi que l'utilisation de ces compositions pour prévenir et/ou traiter les maladies associées à un métabolisme perturbé de la bradykinine ou de ses analogues, chez les humains ou les animaux.

  本发明涉及式(I)的吡啶吡咯酮、喹啉和融合的N-杂环化合物，其中Z是式(a)或(b)的基团，其中X1是N或C-R1，X2是N或C-R9，X3是N或C-R2，R1是低碳基，R2是氢，低碳基等，R9是氢或低碳基，R3是卤素等，R4是卤素等，R5是式(c)等基团，A是低碳基，Y是O等，以及其药学上可接受的盐，其制备方法，包括其的制药组合物，以及在人类或动物中预防和/或治疗缓激肽或其类似物介导的疾病的方法。
• [EN] HETEROCYCLIC COMPOUNDS AS BRADYKININ ANTAGONISTS<br/>[FR] COMPOSES HETEROCYCLIQUES UTILISES COMME ANTAGONISTES DE LA BRADYKININE
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：WO1997011069A1

  公开（公告）日：1997-03-27

  (EN) This invention relates to a compound of formula (I) wherein A1 is lower alkylene, R1 is substituted quinolyl, etc., R2 is hydrogen, halogen or lower alkyl, R3 is halogen or lower alkyl, and R4 is a group of the formula: -Q-A2-R5, etc., in which R5 is amino, acylamino, etc., A2 is lower alkylene or a single bond, and Q is a group of formula (a), and pharmaceutically acceptable salts thereof, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to methods of using the same therapeutically in the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.(FR) Cette invention se rapporte à un composé représenté par la formule (I), où A1 représente alkylène inférieur, R1 représente quinolyle substitué, etc., R2 représente hydrogène, halogène ou alkyle inférieur, R3 représente halogène ou alkyle inférieur, et R4 représente un groupe de la formule: -Q-A2-R5, etc., où R5 représente amino, acylamino, etc., A2 représente alkylène inférieur ou une liaison simple, et Q représente un groupe de la formule (a), etc., ainsi qu'à des sels d'un tel composé, acceptables sur le plan pharmaceutique, à des procédés pour le préparer, à une composition pharmaceutique le contenant, ainsi qu'à des procédés d'utilisation thérapeutique d'un tel composé dans la prévention et/ou le traitement des maladies à médiation par la bradykinine ou ses analogues, chez l'homme ou chez des animaux.

  该发明涉及一种化合物，其化学式为(I)，其中A1为低级烷基，R1为取代的喹啉基等，R2为氢、卤素或低级烷基，R3为卤素或低级烷基，R4为以下式的基团：-Q-A2-R5等，其中R5为氨基、酰胺基等，A2为低级烷基或单键，Q为以下式的基团(a)，以及其药学上可接受的盐，制备该化合物的方法，包含该化合物的药物组合物，以及在预防和/或治疗人类或动物中由激肽酶介导的激肽或其类似物引起的疾病中治疗其的方法。
• Heterocyclic compounds
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05708173A1

  公开（公告）日：1998-01-13

  A compound of the formula: ##STR1## or its salt is prepared by reacting a compound of the formula: ##STR2## with a compound of the formula: ##STR3## Wherein the variables are all defined in claim 1.

  一种化合物的分子式为：##STR1##或其盐，是通过将一种分子式为：##STR2##的化合物与一种分子式为：##STR3##的化合物反应制备而成。其中变量在权利要求书1中被定义。
• Bradykinin antagonist quinolines
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05563162A1

  公开（公告）日：1996-10-08

  This invention relates to new heterocyclic compounds and pharmaceutically acceptable salts thereof. More particularly, this invention relates to new heterocyclic compounds and salts thereof which display bradykinin antagonist activity, to processes for preparing these compounds, to a pharmaceutical composition comprising these compounds, and to methods of using same in the prevention and/or the treatment of bradykinin- or bradykinin analogue-mediated diseases such as allergy, inflammation, autoimmune disease, shock, pain, or the like, in human beings or in animals.

  本发明涉及新的杂环化合物及其药学上可接受的盐。更具体地，本发明涉及新的杂环化合物及其盐，其具有Bradykinin拮抗活性，涉及制备这些化合物的过程，涉及包含这些化合物的制药组合物，以及在人类或动物中预防和/或治疗由Bradykinin或Bradykinin类似物介导的疾病，如过敏、炎症、自身免疫疾病、休克、疼痛等的使用方法。